- Home
- PBFS vs ETON Comparison
PBFS vs ETON Comparison
Compare PBFS & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- ETON
- Stock Information
- Founded
- PBFS 1889
- ETON 2017
- Country
- PBFS United States
- ETON United States
- Employees
- PBFS N/A
- ETON N/A
- Industry
- PBFS Banks
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- ETON Health Care
- Exchange
- PBFS Nasdaq
- ETON Nasdaq
- Market Cap
- PBFS 309.6M
- ETON 329.8M
- IPO Year
- PBFS N/A
- ETON 2018
- Fundamental
- Price
- PBFS $11.68
- ETON $14.22
- Analyst Decision
- PBFS
- ETON Strong Buy
- Analyst Count
- PBFS 0
- ETON 3
- Target Price
- PBFS N/A
- ETON $27.67
- AVG Volume (30 Days)
- PBFS 26.6K
- ETON 248.9K
- Earning Date
- PBFS 05-12-2025
- ETON 03-18-2025
- Dividend Yield
- PBFS N/A
- ETON N/A
- EPS Growth
- PBFS 11.77
- ETON N/A
- EPS
- PBFS 0.76
- ETON N/A
- Revenue
- PBFS $88,118,000.00
- ETON $39,011,000.00
- Revenue This Year
- PBFS N/A
- ETON $107.69
- Revenue Next Year
- PBFS N/A
- ETON $65.50
- P/E Ratio
- PBFS $15.61
- ETON N/A
- Revenue Growth
- PBFS 21.67
- ETON 23.29
- 52 Week Low
- PBFS $8.76
- ETON $3.03
- 52 Week High
- PBFS $12.20
- ETON $18.41
- Technical
- Relative Strength Index (RSI)
- PBFS 44.64
- ETON 43.84
- Support Level
- PBFS $11.76
- ETON $12.73
- Resistance Level
- PBFS $12.04
- ETON $15.73
- Average True Range (ATR)
- PBFS 0.25
- ETON 0.93
- MACD
- PBFS -0.02
- ETON -0.01
- Stochastic Oscillator
- PBFS 11.86
- ETON 49.67
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.